GlioblastomaGLOIOSNCT06490497
Expectations and Needs of a Glioblastoma Caregiver
An observational study of Glioblastoma, run by Hopital Nord Franche-Comte at 1 site in France.
Trial summary
Cancers of the central nervous system have a poor prognosis. Glioblastoma is most common glial tumor of the central nervous system. The presence of a tumour in the brain determines the particular and specific nature of care for these patients and their families. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Glioblastoma
- What is being tested?
- Interview
- How many people
- 9 participants
- Where
- 1 siteFrance
- Study dates
- 26 Jan 2024to 20 Jun 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Caregivers of a person with glioblastoma glioblastoma undergoing oncology treatment
Who may be able to join
- Caregivers of a person with glioblastoma glioblastoma undergoing oncology treatment
- Caregivers aged 18 and over
Who cannot join
- Patient's opposition to participating in the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Analysis of the Expectations and Needs of a Caregiver of a Glioblastoma Patient Undergoing in Oncology
Cancers of the central nervous system have a poor prognosis. Glioblastoma is most common glial tumor of the central nervous system. The presence of a tumour in the brain determines the particular and specific nature of care for these patients and their families. Symptoms affect daily life and the balance of the family sphere.It's easy to imagine a difficult and disturbed family's daily routine.
Caregivers find themselves in great distress but can still benefit from support to lighten the domestic burden, and financial burden, thanks to the various recommendations of successive Cancer Plans. In fact, support for patients and their families during the illness and after is one of the key points of the programs in place. The aim of this research will be to provide food for thought in order to improve the support provided to family and friends.
- Conditions
- Glioblastoma
- Being tested
- Interview
- Keywords
- family caregiver
- Medical subject headings
- Glioblastoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InterviewOther
individual interviews semi-directive
| Study group | Role | What they receive |
|---|---|---|
| Caregiver of a glioblastoma patient undergoing glioblastoma treated in oncology | Not described Receives: Other: Interview |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difficulties and specific needs of a caregiver
Identify the difficulties and specific needs of a caregiver in the particular context of a person with glioblastoma.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2024
- Study start26 Jan 2024
- Primary completion16 Apr 2024
- Study completion20 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlioblastomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 9 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hopital Nord Franche-Comte
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06490497
- Sponsor's protocol ID
- 2023-04
- Acronym
- GLOIOS
- Status last verified
- Jun 2024
- First submitted
- 24 Jun 2024
- Last updated
- 8 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analysis of the Expectations and Needs of a Caregiver of a Glioblastoma Patient Undergoing in Oncology
- ClinicalTrials.gov ID
- NCT06490497
- Acronym / sponsor ID
- GLOIOS / 2023-04
- Conditions
- Glioblastoma
- Keywords
- family caregiver
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 9 participants (actual)
- Lead sponsor
- Hopital Nord Franche-ComteUniversity, hospital or other
- Study start
- 26 Jan 2024 (actual)
- Primary completion
- 16 Apr 2024 (actual)
- Study completion
- 20 Jun 2024 (actual)
- First posted
- 8 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cancers of the central nervous system have a poor prognosis. Glioblastoma is most common glial tumor of the central nervous system. The presence of a tumour in the brain determines the particular and specific nature of care for these patients and their families. Symptoms affect daily life and the balance of the family sphere.It's easy to imagine a difficult and disturbed family's daily routine.
Caregivers find themselves in great distress but can still benefit from support to lighten the domestic burden, and financial burden, thanks to the various recommendations of successive Cancer Plans. In fact, support for patients and their families during the illness and after is one of the key points of the programs in place. The aim of this research will be to provide food for thought in order to improve the support provided to family and friends.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Caregiver of a glioblastoma patient undergoing glioblastoma treated in oncology | – | Other: Interview |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Caregivers of a person with glioblastoma glioblastoma undergoing oncology treatment
Key inclusion criteria (2 listed)
- Caregivers of a person with glioblastoma glioblastoma undergoing oncology treatment
- Caregivers aged 18 and over
Key exclusion criteria (1 listed)
- Patient's opposition to participating in the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Interviewindividual interviews semi-directive | Other | Caregiver of a glioblastoma patient undergoing glioblastoma treated in oncology |
Primary outcome
Difficulties and specific needs of a caregiver
Time frame: Day 1
Identify the difficulties and specific needs of a caregiver in the particular context of a person with glioblastoma.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2024.
- Individual participant dataSharing planned: No
Related trials for Glioblastoma
Active, not recruitingPhase 3
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Glioblastoma
RecruitingPhase 3
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
Glioblastoma
RecruitingPhase 1/2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Active, not recruitingPhase 1
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
Glioblastoma
RecruitingPhase 1/2
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Glioma, Medulloblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glioblastoma, run by Hopital Nord Franche-Comte at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difficulties and specific needs of a caregiver (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2024.